ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

ClinicalTrials.gov ID: NCT00039910

Public ClinicalTrials.gov record NCT00039910. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy

Study identification

NCT ID
NCT00039910
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
240 participants

Conditions and interventions

Interventions

  • (PN-152,243)/ PN-196,444 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2000
Primary completion
Not listed
Completion
Feb 28, 2003
Last update posted
May 3, 2007

2000 – 2003

United States locations

U.S. sites
27
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona 85023
Pfizer Investigational Site La Jolla California 92037
Pfizer Investigational Site Loma Linda California 92354
Pfizer Investigational Site Los Angeles California 90033-0804
Pfizer Investigational Site Los Angeles California 90036
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site Los Angeles California 90089
Pfizer Investigational Site Orange California 92868
Pfizer Investigational Site Tamarac Florida 33321
Pfizer Investigational Site Chicago Illinois 60637
Pfizer Investigational Site Chicago Illinois 60640
Pfizer Investigational Site Lake Charles Louisiana 70601
Pfizer Investigational Site Detroit Michigan 48202
Pfizer Investigational Site Saint Joseph Michigan 49085
Pfizer Investigational Site Southfield Michigan 48076
Pfizer Investigational Site Jefferson City Missouri 65109
Pfizer Investigational Site Jefferson City Missouri 90048
Pfizer Investigational Site Omaha Nebraska 68198
Pfizer Investigational Site Brooklyn New York 11235
Pfizer Investigational Site Durham North Carolina 27705
Pfizer Investigational Site Coos Bay Oregon 97420
Pfizer Investigational Site Hershey Pennsylvania 17033
Pfizer Investigational Site Bristol Tennessee 37620
Pfizer Investigational Site Abingdon Virginia 24210
Pfizer Investigational Site Abingdon Virginia 24211
Pfizer Investigational Site Lebanon Virginia 24266
Pfizer Investigational Site Marion Virginia 24354

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00039910, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2007 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00039910 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →